Alcalay Myriam, Meani Natalia, Gelmetti Vania, Fantozzi Anna, Fagioli Marta, Orleth Annette, Riganelli Daniela, Sebastiani Carla, Cappelli Enrico, Casciari Cristina, Sciurpi Maria Teresa, Mariano Angela Rosa, Minardi Simone Paolo, Luzi Lucilla, Muller Heiko, Di Fiore Pier Paolo, Frosina Guido, Pelicci Pier Giuseppe
Department of Experimental Oncology, European Institute of Oncology, Milan, Italy.
J Clin Invest. 2003 Dec;112(11):1751-61. doi: 10.1172/JCI17595.
Acute myelogenous leukemias (AMLs) are genetically heterogeneous and characterized by chromosomal rearrangements that produce fusion proteins with aberrant transcriptional regulatory activities. Expression of AML fusion proteins in transgenic mice increases the risk of myeloid leukemias, suggesting that they induce a preleukemic state. The underlying molecular and biological mechanisms are, however, unknown. To address this issue, we performed a systematic analysis of fusion protein transcriptional targets. We expressed AML1/ETO, PML/RAR, and PLZF/RAR in U937 hemopoietic precursor cells and measured global gene expression using oligonucleotide chips. We identified 1,555 genes regulated concordantly by at least two fusion proteins that were further validated in patient samples and finally classified according to available functional information. Strikingly, we found that AML fusion proteins induce genes involved in the maintenance of the stem cell phenotype and repress DNA repair genes, mainly of the base excision repair pathway. Functional studies confirmed that ectopic expression of fusion proteins constitutively activates pathways leading to increased stem cell renewal (e.g., the Jagged1/Notch pathway) and provokes accumulation of DNA damage. We propose that expansion of the stem cell compartment and induction of a mutator phenotype are relevant features underlying the leukemic potential of AML-associated fusion proteins.
急性髓系白血病(AML)具有遗传异质性,其特征是染色体重排产生具有异常转录调控活性的融合蛋白。在转基因小鼠中表达AML融合蛋白会增加髓系白血病的风险,这表明它们会诱导白血病前期状态。然而,其潜在的分子和生物学机制尚不清楚。为了解决这个问题,我们对融合蛋白的转录靶点进行了系统分析。我们在U937造血前体细胞中表达AML1/ETO、PML/RAR和PLZF/RAR,并使用寡核苷酸芯片测量全局基因表达。我们鉴定出1555个受至少两种融合蛋白协同调控的基因,这些基因在患者样本中得到了进一步验证,并最终根据现有的功能信息进行了分类。令人惊讶的是,我们发现AML融合蛋白诱导参与维持干细胞表型的基因,并抑制DNA修复基因,主要是碱基切除修复途径的基因。功能研究证实,融合蛋白的异位表达持续激活导致干细胞更新增加的途径(例如,Jagged1/Notch途径),并引发DNA损伤的积累。我们提出,干细胞区室的扩大和突变体表型的诱导是AML相关融合蛋白白血病潜能的相关特征。